The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality ...

Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course ...

The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success ...

The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company." ...

Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to ...

AI is evolving from interactive chats to automated workloads driven by agentic tools, compressing timelines and enabling faster outcomes. A new reference architecture running on the Dell Pro Max with ...

Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three ...

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk ...

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings ...

First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers ...